2 research outputs found
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data
Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR)Â +Â triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life.The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62Â %), enzalutamide (8Â %) and bicalutamide (30Â %). CBR at 6 months was 29Â % (7/24) with 2 CR, 3Â PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic ARÂ +Â TNBC are in line with data from published trials
Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice
Upper tract urothelial carcinoma (UTUC) is a rare disease included, along with the much more frequent urothelial bladder cancer (BUC), in the family of urothelial carcinomas (UCs). However, while UTUCs and BUCs share several features, their epidemiological, clinical, pathological, and biological differences must be considered to establish an optimal therapeutic strategy. This review examines the clinical differences between UTUC and BUC, as well as the main results obtained by molecular screening of the two diseases. The findings of clinical trials, performed in peri-operative and metastatic settings and assessing systemic treatments in UC, are summarised. A comparison of the data obtained for UTUC and BUC suggests improved therapeutic approaches, both in regards to routine practice and future drug development